Fibrolamellar Carcinoma

subtype

Identifier: CI-CAN-00005305
Entity page: /cancer/fibrolamellar-carcinoma ↗
Edges: 48

Neighbours: 1 genes1 variants15 drugs10 trials
Drawn: 27 of 27 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Fibrolamellar Carcinoma diagnostic of …DIAGNOSTIC_OF1 of 1
← diagnostic of	PRKACA Fusionfusion 3 source records aggregated	supports	B	Fibrolamellar Carcinoma	3	Curated	civic	graph →
Fibrolamellar Carcinoma associated with …ASSOCIATED_WITH1 of 1

Fibrolamellar Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 25show all (up to 200)
→ investigated in trials for	Nivolumabmonoclonal antibody 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Afliberceptother 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Dostarlimabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Everolimussmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →

Fibrolamellar Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 25show all (up to 200)

→ investigated in trials for

Nivolumabmonoclonal antibody

3 trials (3 active) · roll-up of the cancer and its descendants

—

Fibrolamellar Carcinoma studied in …STUDIED_INderived10 of 21show all (up to 200)
→ studied in	NCT03533582Phase 3 · active not recruiting Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery · condition mapped ONTOLOGY_EXACT · 21 trials mapped (12 active)	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04380545Phase 1/Phase 2 · recruiting Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer · condition mapped CURATED_BROADER · 21 trials mapped (12 active)	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06789198Phase 1 · recruiting Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA · condition mapped ALIAS · 21 trials mapped (12 active)	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06620302Phase 1/Phase 2 · suspended Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma · condition mapped CURATED_BROADER · 21 trials mapped (12 active)	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05468359Phase 1/Phase 2 · recruiting Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients · condition mapped ONTOLOGY_EXACT · 21 trials mapped (12 active)	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06638931Phase 2 · recruiting Agnostic Therapy in Rare Solid Tumors · condition mapped ONTOLOGY_EXACT · 21 trials mapped (12 active)	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03860272Phase 1 · active not recruiting Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer · condition mapped ONTOLOGY_EXACT · 21 trials mapped (12 active)	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04134559Phase 2 · recruiting Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 21 trials mapped (12 active)	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06027086Phase 1/Phase 2 · recruiting DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) · condition mapped ALIAS · 21 trials mapped (12 active)	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04248569Phase 1 · recruiting DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma · condition mapped ALIAS · 21 trials mapped (12 active)	—	—	Fibrolamellar Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains